Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Combined With Sintilimab and GC as First-Line Therapy for Unresectable Biliary Tract Cancer
NCT07638501Phase 2Not yet recruiting
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, gemcitabine, Cisplatin micelle injection (HA132) in biliary tract cancer (BTC), sponsored by Eastern Hepatobiliary Surgery Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
sintilimabgemcitabineCisplatin micelle injection (HA132)
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07638501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638501.